Trial reportDiabetes, obesity & metabolism2026
Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
Trial report in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsThis study aimed to assess the effects of low-dose tirzepatide combined with metformin (COM) versus metformin (MET) monotherapy in overweight/obese women with polycystic ovary syndrome (PCOS). MATERIALS AND
methodsSixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks. The primary outcome was the change in body weight. Secondary outcomes included changes in anthropometric measures other than body weight, body composition, reproductive hormone levels, metabolic and endocrine parameters, inflammatory markers and menstrual cycle regularity. All outcomes were assessed at baseline and week 16. After week 16, participants were switched to MET monotherapy. Barrier contraception was required for 8 weeks and pregnancy outcomes were subsequently evaluated between weeks 25 and 48.
resultsAfter 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p < 0.001), body mass index (BMI) (-0.68 ± 1.82 vs. -4.12 ± 1.37 kg/m
conclusionsIn overweight/obese women with PCOS, low-dose tirzepatide combined with MET was associated with greater reductions in body weight and visceral fat, along with improvements in metabolic and reproductive outcomes compared with MET monotherapy.
trial registrationChiCTR2400090908; chictr.org.cn.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.